View:

Download DOC

Download PDF

Download XLS

144: Filer Information

Filer CIK	0001970809
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Cellebrite DI Ltd.
SEC File Number	001-40772
Address of Issuer	94 SHLOMO SHMELZER ROAD PETAH TIKVA ISRAEL 4970602
Phone	972-73-394-8000
Name of Person for Whose Account the Securities are To Be Sold	LISA COLE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, par value NIS 0.00001	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Floor New York   NY   10004	1553	17393.60	205932179	05/07/2024	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, par value NIS 0.00001	05/06/2024	Restricted Shares Units Vested Under an Issuer S-8 Registered Plan	Cellebrite DI Ltd.			5182	05/06/2024	Employee compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Lisa Cole c/o Cellebrite DI Ltd. 94 Shlomo Shmelzer Road Petah Tikva   L3   4970602	Ordinary shares, par value NIS 0.00001	02/07/2024	1850	17088.82

144: Remarks and Signature

Remarks	The reporting person sold the securities reported herein on 05/07/2024 pursuant to a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only.
Date of Notice	05/07/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kobi Sahariya, as Attorney-in-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of the following Cellebrite DI Ltd.’s (the “Company”) representatives: Roei Gamadi and / or Kobi Oved and / or Liraz Zilberman and / or Dana Gerner and / or Ayala Berler Shapira and / or Kobi Sahariya, signing singly, the undersigned’s true and lawful attorney-in-fact and agent to:

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Rule 144.

This Power of Attorney shall remain in full force and effect with respect to the undersigned until the earliest to occur of (a) such date that the undersigned is no longer required to file Forms 144 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, or (b) the revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. This Power of Attorney shall terminate with respect to each of the foregoing attorneys-in-fact at such time as such attorney-in-fact is no longer employed by the Company or any of its subsidiaries.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1 day of May 2024.